Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 1.979
Filter
1.
Nano Lett ; 24(28): 8752-8762, 2024 Jul 17.
Article in English | MEDLINE | ID: mdl-38953881

ABSTRACT

Acute methicillin-resistant Staphylococcus aureus (MRSA) pneumonia is a common and serious lung infection with high morbidity and mortality rates. Due to the increasing antibiotic resistance, toxicity, and pathogenicity of MRSA, there is an urgent need to explore effective antibacterial strategies. In this study, we developed a dry powder inhalable formulation which is composed of porous microspheres prepared from poly(lactic-co-glycolic acid) (PLGA), internally loaded with indocyanine green (ICG)-modified, heat-resistant phages that we screened for their high efficacy against MRSA. This formulation can deliver therapeutic doses of ICG-modified active phages to the deep lung tissue infection sites, avoiding rapid clearance by alveolar macrophages. Combined with the synergistic treatment of phage therapy and photothermal therapy, the formulation demonstrates potent bactericidal effects in acute MRSA pneumonia. With its long-term stability at room temperature and inhalable characteristics, this formulation has the potential to be a promising drug for the clinical treatment of MRSA pneumonia.


Subject(s)
Methicillin-Resistant Staphylococcus aureus , Polylactic Acid-Polyglycolic Acid Copolymer , Methicillin-Resistant Staphylococcus aureus/drug effects , Animals , Mice , Polylactic Acid-Polyglycolic Acid Copolymer/chemistry , Microspheres , Photothermal Therapy , Pneumonia, Staphylococcal/therapy , Phage Therapy/methods , Indocyanine Green/chemistry , Indocyanine Green/pharmacology , Indocyanine Green/therapeutic use , Indocyanine Green/administration & dosage , Anti-Bacterial Agents/chemistry , Anti-Bacterial Agents/pharmacology , Anti-Bacterial Agents/administration & dosage , Anti-Bacterial Agents/therapeutic use , Administration, Inhalation , Humans , Bacteriophages/chemistry
2.
Cytokine ; 180: 156662, 2024 Aug.
Article in English | MEDLINE | ID: mdl-38824863

ABSTRACT

BACKGROUND: Previous researches have clarified that miR-155 is increased in methicillin-resistant Staphylococcus aureus (MRSA) pneumonia, and modulates Th9 differentiation. Like Th9 cells, Th17 cells were also a subset of CD4+ T cells and involved in MRSA pneumonia progression. This work aimed to investigate the role and mechanism of miR-155 in Th17 differentiation. METHODS: Bronchoalveolar lavage fluid (BALF) was collected from children with MRSA pneumonia and bronchial foreign bodies. MRSA-infected murine model was established followed by collecting BALF and lung tissues. qRT-PCR, ELISA and flow cytometry were performed to examine the mRNA expression and concentration of IL-17 and the number of Th17 cells in above samples. HE and ELISA were used to evaluate inflammatory responses in lung. Furthermore, CD4+ T cells were isolated from BALF of children for in vitro experiments. After treatments with miR-155 mimic/inhibitor, the roles of miR-155 in Th17/IL-17 regulation were determined. The downstream of miR-155 was explored by qRT-PCR, western blotting, dual luciferase reporter analysis and RIP assay. RESULTS: The levels of IL-17 and the proportion of Th17 cells were increased in children with MRSA pneumonia. A similar pattern was observed in MRSA-infected mice. On the contrary, IL-17 neutralization abolished the activation of Th17/IL-17 induced by MRSA infection. Furthermore, IL-17 blockade diminished the inflammation caused by MRSA. In vitro experiments demonstrated miR-155 positively regulated IL-17 expression and Th17 differentiation. Mechanistically, FOXP3 was a direct target of miR-155. miR-155 inhibited FOXP3 level via binding between FOXP3 and Argonaute 2 (AGO2), the key component of RNA-induced silencing complex (RISC). FOXP3 overexpression reversed elevated IL-17 levels and Th17 differentiation induced by miR-155. CONCLUSIONS: miR-155 facilitates Th17 differentiation by reducing FOXP3 through interaction of AGO2 and FOXP3 to promote the pathogenesis of MRSA pneumonia. IL-17 blockade weakens the inflammation due to MRSA, which provides a nonantibiotic treatment strategy for MRSA pneumonia.


Subject(s)
Cell Differentiation , Forkhead Transcription Factors , Inflammation , Interleukin-17 , Methicillin-Resistant Staphylococcus aureus , MicroRNAs , Th17 Cells , MicroRNAs/genetics , MicroRNAs/metabolism , Th17 Cells/immunology , Th17 Cells/metabolism , Animals , Forkhead Transcription Factors/metabolism , Forkhead Transcription Factors/genetics , Humans , Mice , Interleukin-17/metabolism , Inflammation/metabolism , Male , Bronchoalveolar Lavage Fluid , Female , Child , Pneumonia, Staphylococcal/immunology , Pneumonia, Staphylococcal/metabolism , Pneumonia, Staphylococcal/microbiology , Child, Preschool
3.
Bioorg Chem ; 150: 107559, 2024 Sep.
Article in English | MEDLINE | ID: mdl-38905889

ABSTRACT

A library of new quinazoline pharmacophores bearing benzenesulfonamide moiety was designed and synthesized. Compounds 3a-n were screened for their in vitro antimicrobial activity against eight multidrug-resistant clinical isolates. Compounds 3d and 3n exhibited prominent antibacterial activity, specifically against MRSA. After exhibiting relative in vitro and in vivo safety, compound 3n was selected to assess its anti-inflammatory activity displaying promising COX-2 inhibitory activity compared to Ibuprofen. In vivo experimental MRSA pneumonia model was conducted on immunodeficient (irradiated) mice to reveal the antimicrobial and anti-inflammatory responses of compound 3n compared to azithromycin (AZ). Treatment with compound 3n (10 and 20 mg/kg) as well as AZ resulted in a significant decrease in bacterial counts in lung tissues, suppression of serum C-reactive protein (CRP), lung interleukin-6 (IL-6), myeloperoxidase activity (MPO) and transforming growth factor-ß (TGF-ß). Compound 3n showed a non-significant deviation of lung TGF-ß1 from normal values which in turn controlled the lung inflammatory status and impacted the histopathological results. Molecular docking of 3n showed promising interactions inside the active sites of TGF-ß and COX-2. Our findings present a new dual-target quinazoline benzenesulfonamide derivative 3n, which possesses significant potential for treating MRSA-induced pneumonia in an immunocompromised state.


Subject(s)
Anti-Bacterial Agents , Methicillin-Resistant Staphylococcus aureus , Microbial Sensitivity Tests , Quinazolines , Sulfonamides , Methicillin-Resistant Staphylococcus aureus/drug effects , Animals , Sulfonamides/chemistry , Sulfonamides/pharmacology , Sulfonamides/chemical synthesis , Mice , Quinazolines/pharmacology , Quinazolines/chemistry , Quinazolines/chemical synthesis , Anti-Bacterial Agents/pharmacology , Anti-Bacterial Agents/chemistry , Anti-Bacterial Agents/chemical synthesis , Molecular Structure , Structure-Activity Relationship , Transforming Growth Factor beta/metabolism , Transforming Growth Factor beta/antagonists & inhibitors , Dose-Response Relationship, Drug , Humans , Molecular Docking Simulation , Pneumonia, Staphylococcal/drug therapy
4.
Clin Exp Pharmacol Physiol ; 51(6): e13866, 2024 Jun.
Article in English | MEDLINE | ID: mdl-38719209

ABSTRACT

Staphylococcus aureus (S. aureus) pneumonia has become an increasingly important public health problem. Recent evidence suggests that epigenetic modifications are critical in the host immune defence against pathogen infection. In this study, we found that S. aureus infection induces the expression of histone deacetylase 6 (HDAC6) in a dose-dependent manner. Furthermore, by using a S. aureus pneumonia mouse model, we showed that the HDAC6 inhibitor, tubastatin A, demonstrates a protective effect in S. aureus pneumonia, decreasing the mortality and destruction of lung architecture, reducing the bacterial burden in the lungs and inhibiting inflammatory responses. Mechanistic studies in primary bone marrow-derived macrophages demonstrated that the HDAC6 inhibitors, tubastatin A and tubacin, reduced the intracellular bacterial load by promoting bacterial clearance rather than regulating phagocytosis. Finally, N-acetyl-L- cysteine, a widely used reactive oxygen species (ROS) scavenger, antagonized ROS production and significantly inhibited tubastatin A-induced S. aureus clearance. These findings demonstrate that HDAC6 inhibitors promote the bactericidal activity of macrophages by inducing ROS, an important host factor for S. aureus clearance and production. Our study identified HDAC6 as a suitable epigenetic modification target for preventing S. aureus infection, and tubastatin A as a useful compound in treating S. aureus pneumonia.


Subject(s)
Histone Deacetylase 6 , Histone Deacetylase Inhibitors , Macrophages , Reactive Oxygen Species , Staphylococcus aureus , Animals , Histone Deacetylase 6/antagonists & inhibitors , Histone Deacetylase 6/metabolism , Reactive Oxygen Species/metabolism , Staphylococcus aureus/drug effects , Mice , Macrophages/drug effects , Macrophages/metabolism , Macrophages/microbiology , Histone Deacetylase Inhibitors/pharmacology , Hydroxamic Acids/pharmacology , Pneumonia, Staphylococcal/drug therapy , Pneumonia, Staphylococcal/microbiology , Pneumonia, Staphylococcal/metabolism , Indoles/pharmacology , Mice, Inbred C57BL , Phagocytosis/drug effects , Lung/drug effects , Lung/microbiology , Lung/metabolism , Lung/pathology
5.
Eur J Clin Microbiol Infect Dis ; 43(6): 1247-1250, 2024 Jun.
Article in English | MEDLINE | ID: mdl-38607577

ABSTRACT

Existing recommended first-line antibiotic agents for MRSA pneumonia have several shortcomings. We reviewed 29 cases of community- and hospital-acquired MRSA pneumonia managed at our hospital. Lincosamide monotherapy was administered to 21/29 (72%) and was the predominant antibiotic regimen (> 50% course duration) in 19/29 (66%). Patients receiving lincosamide-predominant monotherapy were no more likely to die or require intensive care unit admission than patients receiving vancomycin-predominant monotherapy (5/19 (26%) versus 4/7 (57%), p = 0.19); 5/7 (71%) patients admitted to ICU and 4/5 (80%) bacteraemic patients received lincosamide-predominant monotherapy. MRSA pneumonia can be safely treated with lincosamide monotherapy if the isolate is susceptible.


Subject(s)
Anti-Bacterial Agents , Lincosamides , Methicillin-Resistant Staphylococcus aureus , Pneumonia, Staphylococcal , Humans , Anti-Bacterial Agents/therapeutic use , Methicillin-Resistant Staphylococcus aureus/drug effects , Methicillin-Resistant Staphylococcus aureus/isolation & purification , Male , Female , Middle Aged , Adult , Pneumonia, Staphylococcal/drug therapy , Pneumonia, Staphylococcal/microbiology , Aged , Australia/epidemiology , Lincosamides/therapeutic use , Lincosamides/pharmacology , Treatment Outcome , Retrospective Studies , Young Adult , Community-Acquired Infections/drug therapy , Community-Acquired Infections/microbiology , Cross Infection/drug therapy , Cross Infection/microbiology , Aged, 80 and over
6.
BMC Infect Dis ; 24(1): 98, 2024 Jan 18.
Article in English | MEDLINE | ID: mdl-38238670

ABSTRACT

INTRODUCTION: Ventilator-associated pneumonia (VAP) is a prominent cause of morbidity and mortality in intensive care unit (ICU) patients. Due to the increase in Methicillin resistant Staphylococcus aureus infection, it is important to consider other more effective and safer alternatives compared to vancomycin. This motivates evaluating whether the use of an apparently more expensive drug such as linezolid can be cost-effective in Colombia. METHODS: A decision tree was used to simulate the results in terms of the cost and proportion of cured patients. In the simulation, patients can receive antibiotic treatment with linezolid (LZD 600 mg IV/12 h) or vancomycin (VCM 15 mg/kg iv/12 h) for 7 days, patients they can experience events adverse (renal failure and thrombocytopenia). The model was analyzed probabilistically, and a value of information analysis was conducted to inform the value of conducting further research to reduce current uncertainties in the evidence base. Cost-effectiveness was evaluated at a willingness-to-pay (WTP) value of US$5180. RESULTS: The mean incremental cost of LZD versus VCM is US$-517. This suggests that LZD is less costly. The proportion of patients cured when treated with LZD compared with VCM is 53 vs. 43%, respectively. The mean incremental benefit of LZD versus VCM is 10 This position of absolute dominance (LZD has lower costs and higher proportion of clinical cure than no supplementation) is unnecessary to estimate the incremental cost-effectiveness ratio. There is uncertainty with a 0.999 probability that LZD is more cost-effective than VCM. Our base-case results were robust to variations in all assumptions and parameters. CONCLUSION: LNZ is a cost-effective strategy for patients, ≥ 18 years of age, with VAP in Colombia- Our study provides evidence that can be used by decision-makers to improve clinical practice guidelines.


Subject(s)
Cross Infection , Methicillin-Resistant Staphylococcus aureus , Pneumonia, Staphylococcal , Pneumonia, Ventilator-Associated , Humans , Linezolid/therapeutic use , Linezolid/pharmacology , Vancomycin/therapeutic use , Cost-Benefit Analysis , Pneumonia, Ventilator-Associated/drug therapy , Colombia , Cross Infection/drug therapy , Anti-Bacterial Agents/pharmacology
7.
Eur Radiol ; 34(8): 5066-5076, 2024 Aug.
Article in English | MEDLINE | ID: mdl-38231392

ABSTRACT

OBJECTIVE: To build and merge a diagnostic model called multi-input DenseNet fused with clinical features (MI-DenseCFNet) for discriminating between Staphylococcus aureus pneumonia (SAP) and Aspergillus pneumonia (ASP) and to evaluate the significant correlation of each clinical feature in determining these two types of pneumonia using a random forest dichotomous diagnosis model. This will enhance diagnostic accuracy and efficiency in distinguishing between SAP and ASP. METHODS: In this study, 60 patients with clinically confirmed SAP and ASP, who were admitted to four large tertiary hospitals in Kunming, China, were included. Thoracic high-resolution CT lung windows of all patients were extracted from the picture archiving and communication system, and the corresponding clinical data of each patient were collected. RESULTS: The MI-DenseCFNet diagnosis model demonstrates an internal validation set with an area under the curve (AUC) of 0.92. Its external validation set demonstrates an AUC of 0.83. The model requires only 10.24s to generate a categorical diagnosis and produce results from 20 cases of data. Compared with high-, mid-, and low-ranking radiologists, the model achieves accuracies of 78% vs. 75% vs. 60% vs. 40%. Eleven significant clinical features were screened by the random forest dichotomous diagnosis model. CONCLUSION: The MI-DenseCFNet multimodal diagnosis model can effectively diagnose SAP and ASP, and its diagnostic performance significantly exceeds that of junior radiologists. The 11 important clinical features were screened in the constructed random forest dichotomous diagnostic model, providing a reference for clinicians. CLINICAL RELEVANCE STATEMENT: MI-DenseCFNet could provide diagnostic assistance for primary hospitals that do not have advanced radiologists, enabling patients with suspected infections like Staphylococcus aureus pneumonia or Aspergillus pneumonia to receive a quicker diagnosis and cut down on the abuse of antibiotics. KEY POINTS: • MI-DenseCFNet combines deep learning neural networks with crucial clinical features to discern between Staphylococcus aureus pneumonia and Aspergillus pneumonia. • The comprehensive group had an area under the curve of 0.92, surpassing the proficiency of junior radiologists. • This model can enhance a primary radiologist's diagnostic capacity.


Subject(s)
Deep Learning , Tomography, X-Ray Computed , Humans , Male , Female , Middle Aged , Diagnosis, Differential , Tomography, X-Ray Computed/methods , Pneumonia, Staphylococcal/diagnostic imaging , Pneumonia, Staphylococcal/microbiology , Aged , Pulmonary Aspergillosis/diagnostic imaging , Staphylococcus aureus/isolation & purification , Adult , Radiographic Image Interpretation, Computer-Assisted/methods
8.
Diagn Microbiol Infect Dis ; 108(2): 116134, 2024 Feb.
Article in English | MEDLINE | ID: mdl-37988933

ABSTRACT

OBJECTIVE: To determine the performance measures of admission methicillin-resistant Staphylococcus aureus (MRSA) nasal swabs for MRSA bacterial pneumonia in patients co-infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). METHODS: The study included patients admitted with SARS-CoV-2-positive nasopharyngeal specimens, MRSA nasal screens, and bacterial cultures to assess secondary MRSA pneumonia. RESULTS: 293 patients and 662 microbiological cultures evaluated. Overall, the specificity (91.8% [95% CI 88.6% to 95%]) and negative predictive value (NPV 97.4% [95% CI 95.4% - 99.3%]) of MRSA nasal swabs was high. However, the sensitivity (46.2%; 95% CI 19.1% to 73.3%) and positive predictive value (PPV 20.7%; 95% CI 59.5 - 35.4%) were low. Those patients in the MRSA nasal swab negative group had a shorter median duration of linezolid therapy. CONCLUSIONS: SARS-CoV-2 infection doesn't reduce the specificity or negative predictive value of MRSA nasal swabs for secondary MRSA pneumonia.


Subject(s)
COVID-19 , Coinfection , Methicillin-Resistant Staphylococcus aureus , Pneumonia, Staphylococcal , Staphylococcal Infections , Humans , Staphylococcal Infections/diagnosis , Staphylococcal Infections/drug therapy , Staphylococcal Infections/microbiology , COVID-19/complications , SARS-CoV-2 , Nose/microbiology , Pneumonia, Staphylococcal/diagnosis , Pneumonia, Staphylococcal/drug therapy , Pneumonia, Staphylococcal/microbiology , Coinfection/diagnosis , Retrospective Studies , Anti-Bacterial Agents/therapeutic use
9.
Int J Antimicrob Agents ; 63(2): 107052, 2024 Feb.
Article in English | MEDLINE | ID: mdl-38072170

ABSTRACT

BACKGROUND: The effect of systemic treatment of ventilator-associated pneumonia (VAP) with telavancin, a semisynthetic lipoglycopeptide with good penetration in vitro biofilms, has not been tested in vivo during mechanical ventilation. This study examined the efficacy of telavancin compared with linezolid against endotracheal tube (ETT) biofilms in a porcine model of methicillin-resistant Staphylococcus aureus (MRSA) VAP. METHODS: VAP was induced in 18 pigs by instilling 107 colony-forming units (CFU/mL) of an MRSA strain susceptible to telavancin and linezolid into each pulmonary lobe. Randomization into three groups was done at pneumonia diagnosis: control (IV glucose 0.5% solution q24); linezolid (10 mg/kg q12) and telavancin groups (22.5 mg/kg q24). After 72 h of MV, data regarding bronchoalveolar lavage (BAL), tracheal aspirate (TA), ETT MRSA biofilm load and thickness measured by scanning electron microscopy were obtained. RESULTS: All 18 pigs completed the study. MRSA was isolated in 100% of ETTs from the control and linezolid groups and in 67% from the telavancin group. Telavancin treatment presented a lower MRSA load compared to the control and linezolid treatments (telavancin median [interquartile range (IQR)] = 1.94 [0.00-5.45], linezolid 3.99 [3.22-4.68] and control 4.93 [4.41-5.15], P = 0.236). Telavancin treatment also resulted in the lowest biofilm thickness according to the SEM (4.04 [2.09-6.00], P < 0.001). We found a positive correlation between ETT and BAL load (rho = 0.511, P = 0.045). CONCLUSIONS: In our VAP model, systemic telavancin treatment reduced ETT MRSA occurrence, load, and biofilm thickness. Our findings may have a bearing on ICU patients' clinical outcomes.


Subject(s)
Aminoglycosides , Methicillin-Resistant Staphylococcus aureus , Pneumonia, Staphylococcal , Pneumonia, Ventilator-Associated , Animals , Anti-Bacterial Agents/therapeutic use , Anti-Bacterial Agents/pharmacology , Biofilms , Intubation, Intratracheal/methods , Linezolid/pharmacology , Linezolid/therapeutic use , Lipoglycopeptides/therapeutic use , Pneumonia, Staphylococcal/drug therapy , Pneumonia, Ventilator-Associated/drug therapy , Swine , Vancomycin/pharmacology , Vancomycin/therapeutic use , Disease Models, Animal
10.
J Immunol ; 212(1): 69-80, 2024 01 01.
Article in English | MEDLINE | ID: mdl-37982695

ABSTRACT

Staphylococcus aureus is a significant cause of morbidity and mortality in pulmonary infections. Patients with autosomal-dominant hyper-IgE syndrome due to STAT3 deficiency are particularly susceptible to acquiring staphylococcal pneumonia associated with lung tissue destruction. Because macrophages are involved in both pathogen defense and inflammation, we investigated the impact of murine myeloid STAT3 deficiency on the macrophage phenotype in vitro and on pathogen clearance and inflammation during murine staphylococcal pneumonia. Murine bone marrow-derived macrophages (BMDM) from STAT3 LysMCre+ knockout or Cre- wild-type littermate controls were challenged with S. aureus, LPS, IL-4, or vehicle control in vitro. Pro- and anti-inflammatory responses as well as polarization and activation markers were analyzed. Mice were infected intratracheally with S. aureus, bronchoalveolar lavage and lungs were harvested, and immunohistofluorescence was performed on lung sections. S. aureus infection of STAT3-deficient BMDM led to an increased proinflammatory cytokine release and to enhanced upregulation of costimulatory MHC class II and CD86. Murine myeloid STAT3 deficiency did not affect pathogen clearance in vitro or in vivo. Matrix metalloproteinase 9 was upregulated in Staphylococcus-treated STAT3-deficient BMDM and in lung tissues of STAT3 knockout mice infected with S. aureus. Moreover, the expression of miR-155 was increased. The enhanced inflammatory responses and upregulation of matrix metalloproteinase 9 and miR-155 expression in murine STAT3-deficient as compared with wild-type macrophages during S. aureus infections may contribute to tissue damage as observed in STAT3-deficient patients during staphylococcal pneumonia.


Subject(s)
Job Syndrome , MicroRNAs , Pneumonia, Staphylococcal , Staphylococcal Infections , Humans , Mice , Animals , Staphylococcus aureus/metabolism , Macrophage Activation , Matrix Metalloproteinase 9/genetics , Matrix Metalloproteinase 9/metabolism , Inflammation/genetics , Mice, Knockout , Mice, Inbred C57BL , STAT3 Transcription Factor/metabolism
11.
Am J Case Rep ; 24: e941088, 2023 Oct 14.
Article in English | MEDLINE | ID: mdl-37837186

ABSTRACT

BACKGROUND Methicillin-resistant Staphylococcus aureus (MRSA) pneumonia is associated with high morbidity and mortality. Recently, MRSA testing by nasal swab has been utilized to "exclude" pneumonia caused by MRSA, given its high negative-predictive value (NPV). We present, however, a case of MRSA pneumonia diagnosed by endotracheal aspirate culture (EAC) in a patient with a negative MRSA nasal swab. CASE REPORT A 58-year-old woman presented with septic shock and respiratory failure. Chest X-ray (CXR) on admission was unrevealing; however, computed tomography (CT) revealed multifocal pneumonia. Intensive Care Unit (ICU)-level care was required for mechanical ventilation and vasopressors. She initially improved with treatment of community-acquired pneumonia (CAP) and was extubated on hospital day 6; however, she then developed a fever, tachycardia, and respiratory distress necessitating re-intubation later that day. Repeat CXR demonstrated a new left lower lobe infiltrate. Blood cultures were drawn and vancomycin and cefepime were started to cover for ventilator-associated pathogens. An EAC and nasal swab were collected to test for MRSA. The next day (day 7), the MRSA nasal swab returned negative, and vancomycin was discontinued. Our patient continued to experience fevers, worsening leukocytosis, and ongoing vasopressor need. On hospital day 9, the EAC results were obtained, and were positive for MRSA. Vancomycin was restarted and our patient recovered. CONCLUSIONS Negative MRSA nasal screening may be considered grounds to de-escalate empiric MRSA antibiotics if MRSA prevalence is low. However, in critically ill patients with high risk and suspicion for MRSA pneumonia, discontinuing empiric MRSA coverage should be done with caution or clinicians should wait until respiratory culture results are obtained before de-escalating antibiotics.


Subject(s)
Methicillin-Resistant Staphylococcus aureus , Pneumonia, Staphylococcal , Staphylococcal Infections , Female , Humans , Middle Aged , Vancomycin , Retrospective Studies , Pneumonia, Staphylococcal/diagnosis , Pneumonia, Staphylococcal/drug therapy , Pneumonia, Staphylococcal/epidemiology , Anti-Bacterial Agents/therapeutic use , Ventilators, Mechanical , Staphylococcal Infections/diagnosis , Staphylococcal Infections/drug therapy
12.
Front Cell Infect Microbiol ; 13: 1230813, 2023.
Article in English | MEDLINE | ID: mdl-37743869

ABSTRACT

Background: Severe community-acquired pneumonia (sCAP) is life-threatening and characterized by intensive care unit (ICU) admission and high mortality. And they are vulnerable to hospital-acquired infection. In such a severe condition, metagenomic next-generation sequencing (mNGS) outperforms for short turnaround time and broad detection spectrum. Case presentation: A 15-year-old male with severe influenza and methicillin-resistant Staphylococcus aureus (MRSA) pneumonia progressed rapidly, initially misdiagnosed as influenza co-infected with Aspergillus for misleading bronchoscopy manifestations. The turnaround time of mNGS is 13 h, which has the potential to expedite the clinical medication process. With the powerful support of mNGS and extracorporeal membrane oxygenation (ECMO), anti-infective therapy was adjusted accordingly, and vital signs gradually stabilized. After tortuous treatment and unremitting efforts, the patient recovered well. Conclusions: Rapid mNGS applications, timely medication adjustments, strong ECMO support and active family compliance contribute to this miracle of life. False-negative or false-positive results are alarming, anti-infective medications should be adjusted after a comprehensive review of physical status and other indicators.


Subject(s)
Cross Infection , Influenza, Human , Methicillin-Resistant Staphylococcus aureus , Pneumonia, Staphylococcal , Male , Humans , Adolescent , Influenza, Human/diagnosis , High-Throughput Nucleotide Sequencing , Pneumonia, Staphylococcal/diagnosis
13.
Infect Immun ; 91(10): e0016623, 2023 10 17.
Article in English | MEDLINE | ID: mdl-37768067

ABSTRACT

In this study, we examined the effect of Il9 deletion on macrophages in methicillin-resistant Staphylococcus aureus (MRSA) infection. MRSA-infected mice were employed for the in vivo experiments, and RAW264.7 cells were stimulated with MRSA for the in vitro experiments. Macrophage polarization was determined by flow cytometry and quantitative real-time PCR; macrophage phagocytosis was assessed by flow cytometry and laser scanning confocal microscopy; cell apoptosis was assessed by flow cytometry and western blotting. Il9 deletion markedly elevated macrophage phagocytosis and M2 macrophages in MRSA infection, which was accompanied by elevated expression of Il10 and Arg1 and reduced expression of Inos, tumor necrosis factor-α (Tnfα), and Il6. Il9 deletion also inhibited macrophage apoptosis in MRSA infection, which was manifested by elevated B-cell lymphoma 2 (BCL-2) protein level and reduced protein levels of cleaved cysteine protease 3 (CASPASE-3) and BCL2-Associated X (BAX). Both the in vivo and in vitro experiments further showed the activation of phosphoinositide 3-kinase (PI3K)/AKT (also known as protein kinase B, PKB) signaling pathway in MRSA infection and that the regulation of Il9 expression may be dependent on Toll-like receptor (TLR) 2/PI3K pathway. The above results showed that Il9 deletion exhibited a protective role against MRSA infection by promoting M2 polarization and phagocytosis of macrophages and the regulation of Il9 partly owing to the activation of TLR2/PI3K pathway, proposing a novel therapeutic strategy for MRSA-infected pneumonia.


Subject(s)
Interleukin-9 , Methicillin-Resistant Staphylococcus aureus , Phagocytosis , Pneumonia, Staphylococcal , Animals , Mice , Interleukin-9/genetics , Interleukin-9/metabolism , Macrophages/metabolism , Methicillin-Resistant Staphylococcus aureus/immunology , Phosphatidylinositol 3-Kinases/metabolism , Pneumonia, Staphylococcal/drug therapy , Pneumonia, Staphylococcal/immunology
14.
Animal Model Exp Med ; 6(6): 585-597, 2023 Dec.
Article in English | MEDLINE | ID: mdl-37246733

ABSTRACT

BACKGROUND: Staphylococcus aureus can cause serious infections by secreting many superantigen exotoxins in "carrier" or "pathogenic" states. HLA DQ and HLA DR humanized mice have been used as a small animal model to study the role of two molecules during S. aureus infection. However, the contribution of HLA DP to S. aureus infection is unknown yet. METHODS: In this study, we have produced HLA DP401 and HLA DRA0101 humanized mice by microinjection of C57BL/6J zygotes. Neo-floxed IAß+/- mice were crossbred with Ella-Cre and further crossbred with HLA DP401 or HLA-DRA0101 humanized mice. After several rounds of traditional crossbreeding, we finally obtained HLA DP401-IAß-/- and HLA DRA-IAß-/- humanized mice, in which human DP401 or DRA0101 molecule was introduced into IAß-/- mice deficient in endogenous murine MHC class II molecules. A transnasal infection murine model of S. aureus pneumonia was induced in the humanized mice by administering 2 × 108 CFU of S. aureus Newman dropwise into the nasal cavity. The immune responses and histopathology changes were further assessed in lungs in these infected mice. RESULTS: We evaluated the local and systemic effects of S. aureus delivered intranasally in HLA DP401-IAß-/- and HLA DRA-IAß-/- transgenic mice. S. aureus Newman infection significantly increased the mRNA level of IL 12p40 in lungs in humanized mice. An increase in IFN-γ and IL-6 protein was observed in HLA DRA-IAß-/- mice. We observed a declining trend in the percentage of F4/80+ macrophages in lungs in HLA DP401-IAß-/- mice and a decreasing ratio of CD4+ to CD8+ T cells in lungs in IAß-/- mice and HLA DP401-IAß-/- mice. A decreasing ratio of Vß3+ to Vß8+ T cells was also found in the lymph node of IAß-/- mice and HLA DP401-IAß-/- mice. S. aureus Newman infection resulted in a weaker pathological injury in lungs in IAß-/- genetic background mice. CONCLUSION: These humanized mice will be an invaluable mouse model to resolve the pathological mechanism of S. aureus pneumonia and study what role DP molecule plays in S. aureus infection.


Subject(s)
Genes, MHC Class II , Pneumonia, Staphylococcal , Mice , Humans , Animals , HLA-DR alpha-Chains/pharmacology , Staphylococcus aureus , Pneumonia, Staphylococcal/genetics , CD8-Positive T-Lymphocytes , Mice, Inbred C57BL , Mice, Transgenic
15.
Int J Biol Macromol ; 242(Pt 1): 124750, 2023 Jul 01.
Article in English | MEDLINE | ID: mdl-37160172

ABSTRACT

Diabetes mellitus (DM) complicated with Staphylococcus aureus (S. aureus) infection lacks effective treatment strategies. In this study, we found that insulin combined with linezolid has potential to deal with the thorny problem. In vitro, our drug sensitivity assay, bacterial growth curve and hemolytic tests showed that a combination of insulin and linezolid exerted good antibacterial and anti-α-hemolysin activity, CCK8 experiment, glucose content and glycogen content determination showed that the combination of insulin and linezolid increased murine macrophage survival rate and reduced the extracellular glucose level of high glucose-treated MH-S cells and intracellular glycogen level, and Western blot showed that the combination inhibited TLR2/MAPKs/NLRP3-related inflammatory pathways in MH-S cells. The results of in vivo experiments showed that the combination therapy stabilized glucose level, remained body weight, ameliorated lung injury including improving pulmonary edema and decreasing lung wet/dry weight ratio, reduced the CFUs and inflammation in the lung tissue in a mouse model of diabetes with S. aureus pneumonia, and inhibited the expression of TLR2, MAPKs and NLRP3 inflammatory pathway. Overall, the combination of insulin and linezolid as autolytic inhibitor exhibited the effects of significant antibacterial and improving glucose level in vitro and in vivo, and also has an anti-inflammation activity via the TLR2/MAPKs/NLRP3 pathway, this paves the way for new treatments for diabetes mellitus complicated with S. aureus infection.


Subject(s)
Diabetes Mellitus , Pneumonia, Staphylococcal , Animals , Mice , Linezolid/pharmacology , Linezolid/metabolism , Linezolid/therapeutic use , Pneumonia, Staphylococcal/drug therapy , Staphylococcus aureus , NLR Family, Pyrin Domain-Containing 3 Protein/metabolism , Toll-Like Receptor 2/metabolism , Insulin/metabolism , Anti-Bacterial Agents/therapeutic use , Diabetes Mellitus/drug therapy
16.
Front Cell Infect Microbiol ; 13: 1162617, 2023.
Article in English | MEDLINE | ID: mdl-37077532

ABSTRACT

Introduction: The bacterial pathogen Staphylococcus aureus harbors numerous virulence factors that impact infection severity. Beyond virulence gene presence or absence, the expression level of virulence proteins is known to vary across S. aureus lineages and isolates. However, the impact of expression level on severity is poorly understood due to the lack of high-throughput quantification methods of virulence proteins. Methods: We present a targeted proteomic approach able to monitor 42 staphylococcal proteins in a single experiment. Using this approach, we compared the quantitative virulomes of 136 S. aureus isolates from a nationwide cohort of French patients with severe community-acquired staphylococcal pneumonia, all requiring intensive care. We used multivariable regression models adjusted for patient baseline health (Charlson comorbidity score) to identify the virulence factors whose in vitro expression level predicted pneumonia severity markers, namely leukopenia and hemoptysis, as well as patient survival. Results: We found that leukopenia was predicted by higher expression of HlgB, Nuc, and Tsst-1 and lower expression of BlaI and HlgC, while hemoptysis was predicted by higher expression of BlaZ and HlgB and lower expression of HlgC. Strikingly, mortality was independently predicted in a dose-dependent fashion by a single phage-encoded virulence factor, the Panton-Valentine leucocidin (PVL), both in logistic (OR 1.28; 95%CI[1.02;1.60]) and survival (HR 1.15; 95%CI[1.02;1.30]) regression models. Discussion: These findings demonstrate that the in vitro expression level of virulence factors can be correlated with infection severity using targeted proteomics, a method that may be adapted to other bacterial pathogens.


Subject(s)
Community-Acquired Infections , Methicillin-Resistant Staphylococcus aureus , Pneumonia, Staphylococcal , Staphylococcal Infections , Humans , Pneumonia, Staphylococcal/microbiology , Staphylococcus aureus , Virulence Factors/genetics , Hemoptysis , Proteomics , Exotoxins/genetics , Staphylococcal Infections/microbiology , Community-Acquired Infections/microbiology , Staphylococcus , Leukocidins/genetics , Methicillin-Resistant Staphylococcus aureus/genetics
17.
Shock ; 59(5): 810-819, 2023 05 01.
Article in English | MEDLINE | ID: mdl-36870071

ABSTRACT

ABSTRACT: In preclinical studies, the protective effects of female sex hormones and the immunosuppressive effects of male sex hormones were demonstrated. However, gender-related differences in multiorgan failure and mortality in clinical trials have not been consistently explained. This study aims to investigate gender-related differences in the development and progression of sepsis using a clinically relevant ovine model of sepsis. Adult Merino male (n=7) and female (n=7) sheep were surgically prepared with multiple catheters before the study. To induce sepsis, bronchoscopy instilled methicillin-resistant Staphylococcus aureus into sheep's lungs. The time from the bacterial inoculation until the modified Quick Sequential Organ Failure Assessment (q-SOFA) score became positive was measured and analyzed primarily. We also compared the SOFA score between these male and female sheep over time. Survival, hemodynamic changes, the severity of pulmonary dysfunction, and microvascular hyperpermeability were also compared. The time from the onset of bacterial inoculation to the positive q-SOFA in male sheep was significantly shorter than in female sheep. Mortality was not different between these sheep (14% vs. 14%). There were no significant differences in hemodynamic changes and pulmonary function between the two groups at any time point. Similar changes in hematocrit, urine output, and fluid balance were observed between females and males. The present data indicate that the onset of multiple organ failure and progression of sepsis is faster in male sheep than in female sheep, even though the severity of cardiopulmonary function is comparable over time. Further studies are warranted to validate the above results.


Subject(s)
Methicillin-Resistant Staphylococcus aureus , Pneumonia, Staphylococcal , Sepsis , Male , Sheep , Animals , Female , Sepsis/drug therapy , Lung/microbiology , Multiple Organ Failure , Gonadal Steroid Hormones/therapeutic use , Retrospective Studies , Prognosis
19.
J Surg Res ; 283: 1047-1052, 2023 03.
Article in English | MEDLINE | ID: mdl-36914995

ABSTRACT

INTRODUCTION: Initiation of broad-spectrum empiric antibiotics is common when infection is suspected in hospitalized adults. The benefits of early utilization of effective antibiotics are well documented. However, the negative effects of inappropriate antibiotic use have led to antimicrobial stewardship mandates. Recent data demonstrate the utility of methicillin-resistant Staphylococcus aureus (MRSA) polymerase chain reaction (PCR) nasal screening to steward anti-MRSA empiric antibiotics in pneumonia. We hypothesize that MRSA PCR nasal swabs would also be effective to rule out other MRSA infection to effectively limit unnecessary antibiotics for any infectious source. METHODS: We performed a single-center retrospective chart review of all adult patient encounters from October 2019-July 2021 with MRSA PCR nasal testing. We then reviewed all charts to evaluate for the presence of infections based on source cultures results, as the gold standard. Sensitivity, specificity, negative predictive value, and positive predictive value were calculated from 2 × 2 contingency tables. RESULTS: Among all patients with MRSA nasal screening, 1189 patients had any infection. Prevalence of MRSA nasal carriage among patients screened was 12%. Prevalence of MRSA infection among all infections was 7.5%. MRSA nasal swabs demonstrated a negative predictive value of 100% for MRSA urinary tract infection, 97.9% for MRSA bacteremia, 97.8% for MRSA pneumonia, 92.1% for MRSA wound infection, and 96.6% for other MRSA infections. Overall, MRSA PCR nasal swabs had a sensitivity of 68.5%, specificity of 90.1%, positive predictive value of 23.7%, and negative predictive value of 98.5% for any infections. CONCLUSIONS: MRSA PCR nasal swabs have a high negative predictive value for all infections. Our data support the use of MRSA PCR nasal swabs to rule out MRSA infection and thereby allow early de-escalation of MRSA coverage in hospitalized patients requiring empiric antibiotics. Implementation of MRSA screening could decrease antibiotic-associated morbidity, resistance, and costs. More studies should be conducted to validate these results and support these findings.


Subject(s)
Antimicrobial Stewardship , Methicillin-Resistant Staphylococcus aureus , Pneumonia, Staphylococcal , Staphylococcal Infections , Adult , Humans , Methicillin-Resistant Staphylococcus aureus/genetics , Staphylococcal Infections/diagnosis , Staphylococcal Infections/drug therapy , Staphylococcal Infections/epidemiology , Retrospective Studies , Pneumonia, Staphylococcal/diagnosis , Pneumonia, Staphylococcal/drug therapy , Anti-Bacterial Agents/therapeutic use , Polymerase Chain Reaction
20.
Diagn. tratamento ; 28(1): 10-14, jan-mar. 2023. ilus 4, tab 1
Article in Portuguese | LILACS | ID: biblio-1413192

ABSTRACT

Contexto: O empiema tem aumentado sua incidência ao longo das últimas décadas e ainda é a complicação mais comum de pneumonias. Apesar dos avanços no tratamento clínico, o acometimento do tecido pleural por infecções pode levar a sequelas irreparáveis e ainda apresenta uma alta mortalidade. Descrição do caso: Paciente do sexo masculino, 55 anos de idade, relatou queixa de dor em hemitórax e ombro esquerdos e parestesia difusa em membro ipsilateral há três dias. Tomografia de tórax revelou empiema pleural em lobo superior esquerdo e eletroneuromiografia evidenciou plexopatia braquial. Foi feita a punção guiada do empiema que demonstrou infecção por Staphylococcus aureus sensível à meticilina. Após drenagem do abscesso e antibioticoterapia, o paciente apresentou melhora progressiva dos sintomas. Discussão: O empiema de necessidade raramente se apresenta secundário a uma infecção bacteriana aguda, sendo geralmente causado por longas efusões pneumônicas tuberculosas. Sua manifestação clínica mais comum é a presença de massa dolorosa na região anterior do tórax, com exames de imagem mostrando alterações inflamatórias. A terapêutica preconizada se constitui de drenagem e antibioticoterapia. Conclusão: O diagnóstico de empiema de necessidade foi poucas vezes descrito na literatura e deve ser suspeitado em quadros infecciosos pulmonares com repercussão neurológica em plexo braquial.


Subject(s)
Humans , Male , Middle Aged , Pneumonia, Staphylococcal , Empyema, Pleural , Pneumonia, Bacterial , Brachial Plexus Neuropathies , Diagnosis
SELECTION OF CITATIONS
SEARCH DETAIL